CD38, a nucleotide-metabolizing ectoenzyme and a receptor, is a negative prognostic marker for chronic lymphocytic leukemia (CLL) patients. CD38 has a genetic polymorphism, with a C-G variation in a putative E-box located in a regulatory region. E2A, the predominant E-box factor in B lymphocytes, was found to be highly expressed by CD38 þ CLL patients. The highest CD38 levels scored by E2A
Introduction
Chronic lymphocytic leukemia (CLL) is characterized by the progressive expansion of a population of functionally incompetent mature B lymphocytes that express CD5 and CD19. 1 The clinical behavior varies widely, ranging from stable conditions not requiring therapy to rapidly advancing disease demanding immediate treatment. Hematologists currently use a limited number of molecular indicators to predict prognosis at diagnosis and to select the optimal therapeutic strategy. 2 Among these markers, CD38 expression above a critical threshold is a widely recognized predictor of shorter overall survival and earlier call for treatment. 3 CD38 is a cell surface type II molecule whose complex and multifunctional ectoenzymatic activity results in the dismantling of nicotinamide adenine dinucleotide and the generation of Ca 2 þ mobilizing compounds. 4 For these reasons, CD38 is part of the family of nucleotide-metabolizing ectoenzymes. CD38 can also bind CD31, a non-substrate ligand predominantly expressed by endothelial and stromal cells. In neoplastic cells, CD38/CD31 interactions initiate a cascade of signals, which lead to increased proliferation, survival and chemotaxis. 5 In vivo, CD38 expression is higher in the bone marrow and in areas of intense CLL/T cell contacts 6 than in the peripheral blood cells. 7 In vitro, CD38 expression can be upregulated during CLL cell activation by a number of different signals, including interleukin (IL)-2, 8 the combination of CD40L and IL-4, 9 cytosine-phosphate-guanine (CpG) oligonucleotides 10 and co-culture with mesenchymal stem cells. 11 Upregulation of CD38 relies on de novo gene transcription and behaves as a polymorphic trait in the population. The human CD38 gene is located on the short arm of chromosome 4 (4p15); transcriptional control is attained at spatially distinct levels. 12 The first level of control lies in the 5 0 flanking promoter region of the gene, which lacks a TATA box and contains a CpG island, suggesting epigenetic regulatory mechanisms. The second is located further upstream from the transcription start site and involves trans interactions. The third level of control is located at the 5 0 end of intron 1. Within this region sits a C-G singlenucleotide polymorphism (SNP), rs6449182, which leads to the presence or absence of a PvuII restriction site. Allelic frequencies have been determined in Italian, Spanish, Irish and Polish populations. [13] [14] [15] [16] Our group recently reported that the frequency of the variant G allele is significantly higher in a subset of CLL patients exhibiting clinical and molecular markers of poor prognosis, with the highest allele frequency scored by patients with Richter's syndrome. 17 The G allele represents an independent risk factor for Richter's syndrome, indicating an additive effect. The same G allele was independently reported as a susceptibility factor for CLL development in a Polish population. 16 No significant differences were found in G carriers and CC homozygotes of either population in terms of the percentage of CD38 þ cells or intensity of expression, at least in circulating CLL lymphocytes. The only distinctive feature was that G carriers upregulated CD38 expression in response to environmental signals more efficiently than CC homozygotes, suggesting that the SNP is involved in transcription. 17 Because the C-G SNP is located within a putative E-box (G(orA)CAXXTGG(orT)), it is possible that it may affect gene transcription through the E47 factor, the predominantly active isoform of the E2A gene in B lymphocytes. E2A is a member of the E-protein family of basic helix-loop-helix proteins. 18 It encodes two E proteins, namely E12 and E47, which are generated by differential splicing of the exon encoding the DNA binding and dimerization domain. 19 E proteins have the ability to bind canonical E-box elements and to activate gene transcription. E proteins are essential in the genetic programs regulating B-cell differentiation, as shown by the absence of precursors and mature B lymphocytes in E2A-null mutant mice. 20 In the B-cell compartment, E2A proteins regulate the expression of several B lineage genes, including l5 21 and early B-cell factor and RAG-1. 22 They also regulate immunoglobulin (Ig) gene transcription and recombination. 19, 23 This study shows that CD38 is a target for E2A in CLL lymphocytes.
Patients and methods

Patients and cells
A total of 72 samples from CLL patients presenting with typical morphology and immunophenotype were obtained after written informed consent in accordance with Institutional Guidelines and Declaration of Helsinki. Standard analyses included CD38 and ZAP-70 stainings (cut-off positivity values of X30 and X20%, respectively), IgVH mutational status (unmutated if X98% homology to the germline gene) and fluorescence in situ hybridization for chromosomes 11, 12, 13 and 17 (Supplementary Table 1 ). CD38 rs6449182 SNP was genotyped as previously described. 17 Venous blood from normal individuals was obtained from the local blood bank. Tonsil samples were collected from children undergoing tonsillectomy, whereas spleens were from transplant donors. B cells were purified by negative selection using anti-CD3, -CD14 and -CD16 antibodies (all produced and in-house purified) and Dynal magnetic beads (Invitrogen, Milano, Italy), with a purity constantly 495%, as checked by double staining with CD5 and CD19. 24 The cell lines used were Nalm-6 (pre-B acute lymphoblastic leukemia) and Raji (Burkitt's lymphoma).
Cell cultures
Purified B-lymphocytes were cultured (2 Â 10 6 per ml) in RPMI-1640 medium (Sigma, Milan, Italy) with 10% fetal calf serum (Seromed, Berlin, Germany), 50 mg/ml gentamicin, 100 U/ml penicillin and 100 mg/ml streptomycin (all from Sigma). Where indicated, recombinant human IL-2 (100 IU/ml) and CpG ODN2006 K (TSGSC STSGSC STSTST STSGST SGSCST STSTST SGSTSG SCSTST) (TibMolBiol, Berlin, Germany) were added for 5-7 days. Cells were then harvested and stained using anti-CD38-FITC (clone A10, produced and conjugated in-house) and CD19-PE (eBioscience, San Diego, CA, USA). An E47-FITC (BD Biosciences, San Jose, CA) monoclonal antibody was used after fixation (4% paraformaldehyde) and permeabilization (0.1% saponin). Cells were analyzed with a FACSort flow cytometer (BD Biosciences), acquiring at least 5000 events per sample. Data were analyzed using the WinMDI software (freely downloadable from http://facs.scripps.edu/software.html) and were expressed either as percentage of positive cells or as mean fluorescence intensity (MFI).
Preparation of cytosolic and nuclear extracts
Purified B-lymphocytes (30 Â 10 6 ) were resuspended in 30 ml of buffer 1 (25 mM HEPES, 5 mM KCl, 0.5 mM MgCl 2 , 1 Â protease mix from Sigma). An equal amount of buffer 2 (buffer 1 þ 1% NP-40) was next added (15 min under rotation). Cells were then centrifuged (2500 g, 1 min), the supernatant recovered as the cytosolic fraction, while the pellet was washed in buffer 2 and resuspended in 50 ml of buffer 3 (25 mM HEPES, 10% sucrose, 350 mM NaCl, 0.01% NP-40, 1 Â protease mix, for 1 h at 4 1C under rotation). Nuclear proteins were recovered by centrifugation (14 000 g, 10 min, 4 1C). Cytosolic and nuclear proteins were quantified using the Bradford method (Bio-Rad, Milan, Italy).
Western blot
Proteins (30 mg, unless otherwise indicated) were resolved by SDS-polyacrylamide gel electrophoresis and analyzed by western blot. The antibodies used were anti-E2A (G98-271 from BD Biosciences), anti-actin (AC-40 from Sigma) and anti-lamin B (C-20, Santa Cruz Biotechnology, Santa Cruz, CA, USA). Densitometric analyses were performed using the NIH ImageJ software (freely downloadable from http://rsbweb.nih.gov/ij/). Relative nuclear E2A expression was calculated as the ratio between the band intensities of E2A and actin. Nuclear extracts from Nalm-6 were used as control and run for each gel, yielding highly comparable E2A values.
Electrophoretic mobility shift assay
Electrophoretic mobility shift assay was done using a non-radioactive method based on biotin-labeled oligos kit (Pierce, Rockford, IL, USA). Full details may be found in Supplementary Materials and Methods.
Chromatin immunoprecipitation
Cells (50 Â 10 6 ) were treated (10 min, 37 1C) with 1% formaldehyde to cross-link proteins to DNA and the reaction quenched by adding 125 mM glycine (5 min, 37 1C). Fixed cells were lysed (10 min, on ice in 10 mM Tris pH 7.6, 1 mM EDTA, 10 mM KCl, 1.5 mM MgCl 2 , 0.1% NP-40, 0.5 mM phenylmethylsulfonyl fluoride and 1 Â protease mix). Nuclei were subsequently lysed by incubating (10 min on ice) with a specific buffer (10 mM Tris, pH 7.6, 1 mM EDTA, 0.1% sodium dodecyl sulfate, 1% Triton X-100, 0.1% Na-deoxycholate, 200 mM NaCl, 0.5 mM phenylmethylsulfonyl fluoride, 1 Â protease mix). Samples were sonicated with a Hielscher UP200S Sonicator (Hielscher, Telow, Germany) (three 10-s cycles at 30% amplitude, on ice) in order to obtain DNA fragments between 1000 and 500 bp. After a preclearing step, 1/20 of the supernatant was kept as the input DNA, whereas the rest was divided in equal parts and incubated (12 h at 4 1C) with an anti-E47 (N-649, Santa Cruz Biotechnology) or pre-immune control rabbit serum. DNA was precipitated with protein-G agarose coupled to salmon-sperm DNA (50 ml, 1 h, 4 1C) (Sigma). Recovered beads were extensively washed and immunocomplexes eluted from beads (10 min, 65 1C) with a buffer containing 50 mM Tris, pH 8, 10 mM EDTA and 1% sodium dodecyl sulfate. Cross-linked DNA protein complexes were reversed by adding 21 ml of 4 M NaCl to eluate and input DNA (5 h, 65 1C). RNA and proteins were removed by RNase A and Proteinase K (both from Quiagen, Milan, Italy), respectively. DNA was purified with phenol/chloroform/isoamylalcohol (25:24:1), followed by chloroform/isoamylalcohol (24:1) and precipitated with 2.5 volumes of ethanol and 1/10 3 M ammonium acetate (1 h, À80 1C). Dry pellets were resuspended in water and amplified using the following specific primers: sense 5 0 -CCACCAAGCGCTTTCCCGAGAC-3 0 and antisense 5 0 -CGAGCCCGGGACTCCCTACTCA-3 0 . Allele quantification was performed by amplifying input or E47-immunoprecipitated DNA with the following primers:
0 (forward G specific) and 5 0 -CTACGCAGCAGAGCCACCGAGCAG-3 0 (antisense). The amplified DNA was digested using the PVUII enzyme (10 IU, 1 h, 37 1C) (Roche, Milan, Italy) and run on an agarose gel. Band intensities were calculated using the ImageQuant TL software (GE Healthcare, Milan, Italy).
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Silencing of E2A
E2A short-hairpin RNA lentiviral particles (Santa Cruz Biotechnology) were used to inhibit E2A expression in Raji and Nalm-6 cell lines, following manufacturer's instructions. Stably infected clones were selected using puromycin (Sigma).
Statistical analyses
Categorical variables were compared by w 2 -test, r Fisher's exact test as appropriate. Continuous variables were compared by the Student's t-test, or by Mann-Whitney test as indicated. Correlation between continuous variables was assessed by measuring the Pearson's correlation coefficient. All statistical tests were two-sided. Multiple regression was used to establish the contribution of CD38 rs6449182 SNP (CC vs CG vs GG), E2A expression (o0.8 vs 40.8), CD38 rs6449182genotype*E2A expression interaction, IGHV mutation status (M vs UM) and ZAP70 expression (o20 vs X20%) in explaining the variance of CD38 expression in the study cohort. As independent variables were managed as dummy variables, significance was assessed by using the incremental F-test applied to R 2 changes. Lack of deviations from logistic regression assumptions were verified for the final model.
Results
E2A is expressed by CLL cells
CD38 C/G SNP in intron-1 is located in a consensus sequence for the E-box family of transcription factors that contain the basic helix-loop-helix structural motif. The binding of transcription factors to E-boxes (or related variant sequences) enhances transcription of the controlled gene. 19, 25 Because of its essential role in B-cell development, 25, 26 attention was focused on the TCF3 gene (also called E2A and used throughout this work), which encodes the E12/E47 transcription factors through alternative splicing. The working hypothesis of this study is that E2A is a transcriptional regulator of CD38 expression, at least in the CLL model.
Expression of E2A was tested in a CLL cohort of 72 patients with a detailed clinical and molecular characterization (Supplementary Table 1) , by setting up a quantitative assay based on western blot analysis of the nuclear vs cytosolic fractions of purified B lymphocytes. The relative E2A expression was standardized using actin as reference loading control and the Nalm-6 cell line as calibrator. 27 In all experiments, E2A expression was restricted to the nucleus, as confirmed by the use of lamin B as a specific marker. The scan of a representative film is shown in Figure 1a . The first finding is that E2A is expressed by the majority of CLL patients (69/72, 95.8%). However, the intensity of the band is highly variable in the CLL sample analyzed (mean values of 0.74 ± 0.06, Figure 1b) . Second, the E2A protein is undetectable in circulating B lymphocytes (n ¼ 5, Po0.0001 when compared with CLL lymphocytes), as well as in splenocytes (n ¼ 6, Po0.0001 when compared with CLL lymphocytes), all from healthy adult donors (mean age 38.8 years, range from 21 to 55 years). It is variably expressed by tonsil B lymphocytes (n ¼ 6, P ¼ 0.09 when compared with CLL lymphocytes), obtained from children undergoing tonsillectomy (mean age 5.9 years, range from 4 to 7 years, Figure 1b) . Globally considered, CLL lymphocytes expressed E2A at significantly higher levels than normal B cells (Po0.0001, Figure 1b) .
Nuclear E2A and surface CD38 are linked
The hypothesis that E2A regulates the transcription of the CD38 gene is supported by the relationship in CLL cells between nuclear E2A and surface CD38 expression. When treated as continuous variables, a linear positive correlation was observed between E2A and the percentage of CD38 Figure 2c) . The relationship between E2A and CD38 was further analyzed by setting a cut-off value for relative E2A expression at 0.8, selected by ROC analysis as the value that best discriminated between CD38 þ and CD38 À patients. A 30% cut-off, the one commonly adopted in clinics, was used for CD38 expression. E2A þ CLL patients displayed a percentage of CD38 þ CLL lymphocytes significantly higher than the E2A À counterpart. The median percentage of CD38 expression was four times higher than that of the E2A À subset (36 vs 8%, Mann-Whitney P ¼ 0.01, Figure 2b ). The CD38 epitope density detected in E2A þ patients was also significantly higher than that of the E2A À counterpart (median MFI values 15 vs 7.6, Mann-Whitney P ¼ 0.007, Figure 2d ). Figure 1 Heterogeneous expression of E2A by CLL cells. (a) B lymphocytes were purified from peripheral blood mononuclear cells of CLL patients or normal donors, spleen and tonsils. After lysis, cytoplasmic and nuclear extracts were run separately and immunoblotted using an anti-E2A-specific monoclonal antibody. Lamin B was included as appropriate nuclear control. Actin showed comparable protein loading in all fractions. (b) Relative nuclear E2A expression was calculated as the ratio between the band intensities of E2A and actin, by using the Nalm-6 cell line as calibrator. Each dot identifies a different patient or donor.
E2A
þ CLL patients were also characterized by higher ZAP-70 levels (median percentage of expression 10.8 vs 4 in the E2A À subset), although statistical significance was not reached (Mann-Whitney P ¼ 0.1, Supplementary Figure 1B) . When treated as continuous variables no correlation was observed between nuclear E2A levels and percentage of ZAP-70
þ patients showed a significantly lower rate of somatic mutations in the IgVH genes than E2A
À ones (Mann-Whitney P ¼ 0.018, Supplementary Figure 1D ), but no correlation was observed when they were treated as continuous variables (Pearson's R ¼ 0.05, P ¼ 0.08, Supplementary Figure 1C) . The results obtained from the analysis of this CLL sample indicate that the most significant degree of association is between E2A and CD38.
The second hypothesis behind this work is that the affinity of E2A for the E-box containing the CD38 minor G SNP is higher than that for the common C allele. This hypothesis is supported by the results of multiple regression analysis: the concomitant presence of E2A expression (40.8) and of CD38 GC/GG genotype is a determinant for the variance in the percentage (b ¼ 0.25, P ¼ 0.027) and MFI (b ¼ 0.36, P ¼ 0.002) of CD38 expression, at least in this study cohort (Table 1) . CD38 variance in expression is not determined by E2A40.8 or by the GC/GG genotypes when considered independently ( Table 1 ). The absence of mutations in the IgVH genes and ZAP-70 expression above the 20% threshold were included as molecular markers known to be associated with CD38 expression, as confirmed in this study cohort.
These results indirectly support the view that E2A enhances the expression of CD38 and that the presence of the G allele within the E-box is followed by a more efficient gene transcription and bona fide surface expression. 
allele
Electrophoretic mobility shift assay and chromatin immunoprecipitation assays were used to obtain evidence that E2A (i) recognizes the E-box present in the CD38 regulatory region and that (ii) it shows differential affinities with the G and C genotypes of the CD38 gene. Nuclear extracts were obtained from Nalm-6, a human B cell line expressing high amounts of E2A protein. 28 Experiments were done using biotin-labeled duplex oligonucleotide probes containing C or G (E-box C and G, respectively, Supplementary   Figure 2A) . Results indicate that the nuclear extracts bind to the E-boxes C and G (Supplementary Figure 1B, lanes 2) . The signal shift is not apparent when the experiments are run in competition with excess unlabeled probes (Supplementary Figure 2B, lanes 3) . The binding affinity was tested by comparing band shifts obtained by incubating dilutions of the nuclear extracts with the biotin-labeled duplex oligonucleotides C or G probes. The presence of a G nucleotide in the central core of the E-box is paralleled by a relatively higher binding affinity (Supplementary Figure 2C) . This finding is in line with previous reports about the identification of the kE2 motif in the enhancer of Igk light chain as the preferred binding site for E2A. 23 Indeed, the E-box G and the kE2 element share an identical CAGGT motif.
The results indicate that a protein present in the nuclear extracts from Nalm-6 specifically binds the E-box site of the intronic enhancer of the human CD38 gene. Furthermore, its affinity for G is higher than that for C. Out of more than 20 B cell lines tested, Nalm-6 and Raji were selected as models because they express E2A at comparable levels, but display different CD38 genotypes (GC and CC, respectively, Supplementary Figure 3A) . Unfortunately, no E2A þ /CD38 þ GG B cell line was available in our collection. Nalm-6 and Raji cells were used to validate the hypothesis that E2A is directly recruited to the E-box element in CD38. Following formaldehyde treatment of the cells, chromatin was isolated and immunoprecipitated using an anti-serum specifically recognizing E47, the predominantly active isoform of E2A. The precipitated DNA was amplified using primers specific for the E-box element of CD38 and analyzed by DNA gel electrophoresis. The relative E2A/E47 binding was calculated by the ratio obtained by comparing the intensities of the immunoprecipitated bands and that of the input bands. Results indicate that E2A/E47 binds to the E-box of the CD38 gene in both cell lines, but that recruitment is significantly higher in Nalm-6 (Figures 3a and b) that carries the GC genotype of CD38. This result suggests that the E2A/E47 protein is characterized by a higher binding affinity to the E-box G. To provide a quantitative approach, a second PCR was performed using the same immunoprecipitated DNA, amplified with forward and reverse primers binding close to the E-box and a third primer designed to be allele-specific. The amplified DNA was then digested using the PVUII enzyme and run in an agarose gel. The presence of a single band in each lane (Figure 3c E2A regulates CD38 gene transcription I Saborit-Villarroya et al confirms the specificity of the primers. The relative allele quantification was obtained by calculating a G/C ratio, significantly higher in the DNA obtained after immunoprecipitation with an anti-E2A/E47 antibody than in the input DNA (Figure 3d ).
This observation was validated in CLL samples using B lymphocytes purified from CD38 þ patients. The samples were categorized on the basis of CD38 genotype (CC or G carriers) and of homogeneous E2A levels (Supplementary Figure 3B) . Chromatin immunoprecipitation assays confirmed that E2A/E47 is actively recruited to the intronic enhancer regulatory region containing the E-box element (Figure 3e ). The binding of E2A/E47 is significantly higher in the presence of the G allele, as highlighted by using sequential dilutions of the precipitated DNA (Figures 3e and f) .
E2A silencing downregulates CD38 expression
A direct relationship between nuclear E2A and surface CD38 expression was demonstrated by generating E2A-deficient cell lines. Lentiviral infection with short-hairpin RNA specific for E2A, antibiotic selection and cellular subcloning provided Raji and Nalm-6 cells featuring a stably silenced E2A expression. This was shown by western blot using lysates derived from cultures synchronized by starvation and subsequent refeeding. Actin was used as internal reference control, showing comparable protein levels in all conditions (Figures 4a and b) . Infection with an empty virus and an identical selection and culture regimen did not modify the constitutive E2A levels (Figure 4) . The results were confirmed by immunofluorescence exploiting a different antibody against E2A, specifically binding the E2A/E47 isoform (Figures 4c and d) . Figure 4 Downregulation of CD38 expression after E2A silencing. Raji and Nalm-6 cells were infected with lentiviruses carrying short-hairpin RNA for E2A and further clonally selected. E2A and CD38 expressions were checked by western blot (a, b) and confirmed by flow cytometry using independent reagents (c, d). Lentiviruses containing GFP proteins were used as controls. Actin antibodies were used to check for equal protein loading. Representative results obtained after analyzing five independent clones per each cell line. (Figures 4a and b) , and confirmed by immunofluorescence, using synchronized cells (Figures 4c and d) . CD19 expression was unmodified by lentiviral infections with both particles. A relevant fraction (31% for Raji and 47% for Nalm-6) of the E2A-silenced clone remained CD38 þ , suggesting that factors other than E2A contribute to gene transcription.
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Direct functional interplay between E2A and CD38 in CLL cells
The presence of the G allele is not accompanied by increased surface CD38 levels in circulating CLL B lymphocytes. 16, 17 However, there is a correlation in terms of induction of CD38 after environmental signals, such as IL-2 8 alone or in combination with CpG oligonucleotides. 10 In light of the results obtained, the observed CD38 upregulation might be secondary to E2A binding to the intronic enhancer in the regulatory region of the CD38 gene. The presence of a G allele would be followed by increased E2A binding and in turn by a significantly higher CD38 upregulation than that scored by CC homozygotes.
To test this hypothesis, a combination of IL-2 and CpG, the TLR-9 ligand was used to induce maximal CD38 expression in a population of 25 CLL patients with known CD38 genotype and basal E2A levels. The kinetics of CD38 upregulation was preliminarily checked in a pilot sample of four patients and expressed as ratio between the MFI values after IL-2/CpG treatment/baseline levels; day 6 was selected as the optimal reading time point. Culture in complete medium without IL-2/CpG was not followed by relevant modifications in CD38 expression by residual live CLL cells (not shown).
The response observed in the 25 CLL samples studied was highly heterogeneous (range 0.8-27.5, mean value 5.96), with 11/25 (44%) patients showing a relative MFI increase below two. A trend towards significance (P ¼ 0.24) between CD38 upregulation and the percentage of IgVH mutations was observed, in agreement with previous results linking the proliferative response to CpG oligonucleotides to the IgVH mutational status. By adopting the same 0.8 cut-off for E2A expression as detailed above, E2A
À patients homogeneously failed to upmodulate CD38 expression in response to IL-2/CpG (range 1-3.4, mean value 1.66). On the contrary, E2A
þ patients maintained a highly variable response (range 0.8-27.5, mean value 8.37, P ¼ 0.03) (Figure 5a Figure 5b) , suggesting that the G allele have an additive effect.
Representative examples of CD38 upregulation in response to IL-2/CpG treatment are reported in Figure 5c , obtained using prototypic CLL lymphocytes purified from CC, GC and GG individuals with comparable basal E2A levels. The treatment did not significantly influence E2A expression, which remained comparable to baseline levels and similar to those of residual live cells cultured in the absence of IL-2/CpG (not shown). E2A regulates CD38 gene transcription I Saborit-Villarroya et al E2A À patients did not upregulate E2A after IL-2/CpG treatment ( Figure 5c ).
E2A binding to the CD38 E-box was confirmed using chromatin immunoprecipitation experiments. IL-2/CpG exposure was followed by a marked increase in the amount of E2A proteins bound to the CD38 regulatory region (Figure 5d ). An internal confirm of the working hypothesis came from the observation that the GC patient featuring basal CD38 expression of 22% (Figure 5b, middle panel) showed constitutive binding of E2A/E47 to the regulatory region. Band intensity was more apparent in the presence of IL-2/CpG, with a consequent 15-fold increase in CD38 MFI.
Discussion
The clinical heterogeneity characterizing CLL cannot be fully accounted for by the nature or the differentiation step of the cell of origin. Polymorphisms in genes coding for molecules critical in disease development and progression are likely to represent key factors in the amplification of intrinsic biological differences, resulting in clinically distinct outcomes. Several reports have indeed associated one or more SNPs to disease susceptibility, prognosis and response to therapy (refs 17, 29-33 , among the others). However, few mechanistic studies have so far addressed the functional impact that SNPs in regulatory regions have on the control of gene expression. The CD38 gene contains a C-G SNP located in an area critical for gene transcription. A selective increase in the frequency of the minor G allele was previously associated to disease susceptibility in a Polish cohort and represented a risk factor for RS in Italian patients. Evidence obtained in this work indicates that the SNP is located within a potential binding site for the E2A transcription factor. The initial finding of the study is that E2A is expressed by CLL cells, whereas it is absent (or undetectable) in normal B lymphocytes obtained from peripheral blood or spleen of adult donors. The latter observation is consistent with data obtained in mice, wherein E2A is undetectable in resting splenic and mature B cells. 34, 35 This observation provides indirect confirmation of a recent study reporting an inverse relationship between E2A expression and age. Indeed, E2A mRNA levels progressively decline with age, both in human and mouse B lymphocytes. 36, 37 The presence of E2A in B lymphocytes from tonsils from children undergoing tonsillectomy further highlights the connection between E2A expression, age and activation. This finding is confirmed by histological analyses performed on hyperplastic tonsils. 38 The emerging pattern of expression of E2A in the human B-cell compartment is strikingly reminiscent of that characterizing CD38. Both molecules are highly expressed by precursor B cells, downregulated during maturation and re-expressed within the germinal center and during plasma cell differentiation. 4, 20 Analysis of a randomly collected CLL cohort provided evidence of a clear-cut positive association between the presence of E2A in the nucleus and surface expression of CD38. The majority of discordant patients were E2A þ but CD38 À , implying that other genetic or epigenetic mechanisms contribute to the initiation of CD38 gene transcription. A second finding concerns the positive association between E2A and ZAP-70 and between E2A and the absence of mutations in the IgVH genes. This observation could simply reflect the known association between independent negative prognostic markers in CLL. A second hypothesis is that E2A could have a role also in the activation of transcription of ZAP-70. According to this hypothesis, E2A could function as a regulator of genetic programs underlying in part the aggressive phenotype, an aspect that deserves deeper investigations.
The second finding of this work is that the CD38 genotype may influence E2A binding, thereby affecting transcription: indirect evidence confirming this finding was collected by analyzing the cohort. No association between the intensity of CD38 expression and its genotype could be found, confirming previous results. 16, 17 Likewise, E2A expression and the CD38 genotype were not associated. However, the combination of E2A þ and a G carrier genotype (GC þ GG) led to the definition of a subgroup of CLL patients with surface levels of CD38 higher than any of the three other categories of patients (E2A þ /CC, E2A À /G carriers, E2A À /CC). In a multivariate analysis, the combination of E2A þ and GC/GG genotype was a significant determinant of the variance in CD38 expression.
We can thus trace three lines of evidence pointing to a direct functional relationship between E2A and CD38. The first line of evidence indicates that E47, the predominantly active isoform of the E2A gene, is effectively recruited to the regulatory region of CD38 and that the CD38 genotype in the E-box conditions the strength of the binding. This observation was originally derived from cell line models and was later confirmed in CLL patients with comparable E2A levels. Second, CD38 surface levels were reduced in B cell lines where E2A had been effectively silenced. The final element linking E2A and CD38 was obtained by mimicking in vitro conditions known to induce CD38 expression through de novo gene transcription. The combined effects of TLR-9 ligands and IL-2 on surface CD38 levels were highly heterogeneous, with some cells undergoing an exponential increase in CD38 expression, whereas others experienced no increase at all. These wide variations may find an explanation at least in two factors conditioning regulation of CD38 gene transcription. The first is that E2A is clearly a necessary requirement, as E2A À patients were homogeneously unresponsive to IL-2 /TLR-9 signaling. The second involves the genotype in the regulatory region of CD38. The presence of the G allele marked cells upregulating CD38 expression; homozygosity for G identified a subset of high responders, pointing to a quantitative effect.
The results of this work may be read from different perspectives. The finding of E2A expression in a subset of CLL patients provides new information in the quest for the cell of origin and the developmental stage in which leukemic transformation occurred. Besides its known and non-redundant role in B-cell development at the early progenitor stage, 39 E2A is now believed to take part in all the major B-cell differentiation steps. In immature B cells expressing an autoreactive BCR, E2A allows survival and RAG gene expression, whereas in mature B lymphocytes it facilitates development towards the follicular cell, at the expense of marginal zone B cells, 35 presumably the source of the CLL precursor. Within the germinal center, E2A is abundant in centroblasts, 40 where it directly regulates the transcription of the AID gene, 41 in turn responsible for class switch recombination and somatic hypermutation. 42 This latter finding, together with a recent report on the expression of AID by a subset of CLL patients characterized by high CD38 levels, 43 suggests a functional relationship between E2A and AID. It also raises questions as to whether CD38 is simply a target of E2A or whether the two players are reciprocally linked. These issues are currently being addressed.
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